Zusammenfassung
Das maligne Melanom ist weltweit in Zunahme begriffen. Obwohl es nur 5% aller Hauttumoren ausmacht, sind mehr als 75% aller durch Hautkrebs verursachten Todesfälle auf ein malignes Melanom zurückzuführen. Während 1935 das Risiko für einen Amerikaner, während seines Lebens an einem malignen Melanom zu erkranken, bei 1:1.500 lag, betrug es 1991 schon 1:105 und wird für das Jahr 2000 auf 1:75 geschätzt (Boring et al. 1994; Harris et al. 1995). Die Inzidenz des malignen Melanoms nimmt schneller als die jeder anderen Krebsart zu, sie stieg in den Vereinigten Staaten seit 1973 jährlich um 4–6%. In den USA erkranken derzeit jährlich etwa 32.000 Menschen, 6.500 sterben pro Jahr an einem malignen Melanom; bei Frauen ist es der häufigste Tumor zwischen 20 und 29 Jahren (Friedman et al. 1991; Katsambas u. Nicolaidou 1996; Kof 1991; Johnson et al. 1994; Schneider et al. 1994).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL (1993) Evaluation of breast masses and axillary lymph nodes with (F18)-2-deoxy-2-fluoro-D-Glucose PET. Radiology 187: 743–750
Armstrong BK, Kricker A (1993) How much melanoma is caused by sun exposure? Mel Res 3: 395–401
Balch CM (1988) The role of elective lymph node dissection in melanoma: rationale, results, and controversie. J Clin Oncol 6: 163–172
Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G (1995) Positron emission tomography and ultrasonography — a comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 131: 1394–1398
Böni R (1996) Whole-body positron emission tomography: an accurate staging modality for metastatic melanoma. Arch Dermatol 132: 833–834
Böni R, Huch-Böni R, Steinert H, Dummer R, Burg G, von Schult-hess GK (1995a) Anti-melanoma monoclonal antibody 225.28 S immunoscintigraphy in metastatic melanoma. Dermatology 191: 119–123
Böni R, Huch-Böni RA, Steinert H et al. (1995b) Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 132: 556–562
Böni R, Huch-Böni RA, Steinert H, von Schulthess GK, Burg G (1996) Early detection of melanoma metastasis using fludeoxy-glucose F-18 positron emission tomography. Arch Dermatol 132: 875–876
Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics. CA Cancer J C 44: 7–26
Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902–908
Chin R, Ward R, Keyes JW et al. (1995) Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care 152: 2090–2096
Divigi CR, Larson SM (1989) Radiolabelled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Semin Nucl Med: 252–261
Fornage BD, Lorigan JG (1989) Sonographic detection and fine-needle aspiration biopsy of nonpalpable recurrent or metastatic melanoma in subcutaneous tissues. J Ultrasound Med 8: 421–424
Friedman RJ, Rigel DS, Silverman MK, Kopf AW, Vossaert KA (1990) Malignant melanoma in the 1990’s. CA Cancer J Clin 41: 201–206
Godellas CV, Berman CG, Lyman G et al. (1995) The identification and mapping of melanoma regional nodal metastases: Minimally invasive surgery for the diagnosis of nodal metastases. Am Surg 61: 97–101
Gritters LS, Francis IR, Zasadny KR, Wahl RL (1993) Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma. J Nucl Med 34: 1420–7
Grünwald F, Schomburg A, Bender H et al. (1996) Fluorine-18 fluo-rodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23: 312–319
Harris MN, Shapiro RL, Roses DF (1995) Malignant melanoma primary surgical management (excision and node dissection) based on pathology and staging. Cancer Suppl 75: 715–725
Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, von Schulthess GK (1993) The value of bone scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumors: a prospective study. Eur J Nucl Med 20: 1063–1069
Horgan K, Hughes LE (1993) Staging of melanoma. Clin Radiol 48: 297–300
Huzaid AC, Sandler AB, Mani S et al. (1993) Role of computed tomography in the staging of malignant melanoma. J Clin Oncol 11: 638–43
Johnson N, Mant D, Newton J, Yudkin PL (1994) Role of primary care in the prevention of malignant melanoma. Br J Gen Pract 44: 523–526
Kagan R, Witt T, Bines S, Mesleh G, Economou S (1988) Gallium-67 scanning for malignant melanoma. Cancer 61: 272–274
Katsambas A, Nicolaidou E (1996) Cutaneous malignant melanoma and sun exposure — recent developments in epidemiology. Arch Dermatol 132: 444–450
Koh HK (1991) Cutaneous melanoma. N Engl J Med 325: 171–182
Kopf AW, Gross DF, Rogers GS et al. (1987) Prognostic index for malignant melanoma. Cancer 59: 1236–1241
Lyons JH, Cockerell CJ (1994) Elective lymph node dissection for melanoma. J Am Acad Dermatol 30: 467–480
MacKie RM, Hole DJ (1996) Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. BMJ 312: 1125–1128
Melia J, Cooper EJ, Frost T et al. (1995) Cancer Research Campaign health education programme to promote the early detection of cutaneous malignant melanoma. II Characteristics and incidence of melanoma. Br J Dermatol 132: 414–421
Rigo P, Paulus P, Kaschten BJ et al. (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxy-glucose. Eur J Nucl Med 23: 1641–1674
Rinne D, Baum RP, Hör G, Kaufmann R (1998) Primary staging and follow-up of high-risk melanoma patients by whole-body F-18-FDG positron-emission-tomography (PET): results of a prospective study in 100 patients. Cancer 82:1664–1671 (im Druck)
Rogers GS, Kopf AW, Rigel DS et al. (1983) Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch Dermatol 119: 644–649
Sasaki M, Ichiya Y, Kuwabara Y et al. (1996) The usefulness of FDG positron emission tomography for the detection of lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 23: 741–747
Schneider JS, Moore DH, Sagebiel RW (1994) Risk factors for melanoma incidence in prospective follow-up. Arch Dermatol 130: 1002–1007
Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ (1996) Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thor Cardiovasc Surg 111: 642–648
Scotto J, Pitcher H, Lee JAH (1991) Indications of future decreasing trends in skin-melanoma mortality among whites in the United States. Int J Cancer 49: 490–497
Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastasic prostate cancer: initial findings of PET with 2-Deoxy-2-[F-18]fluoro-D-glucose. Radiology 199: 751–756
Steinert HC, Huch-Böni RA, Buck A et al. (1995) Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-Fluoro-2-deoxy-D-glucose. Radiology 195: 705–709
Steinert HC, Ullrich SP, Böni R, von Schulthess GK, Dummer R (1998) Kosteneffektivität beim Staging des malignen Melanoms: Vergleich Ganzkörper-PET versus Konventionelles Staging. Nuklearmedizin 37: A37 [Abstr]
Stoelben E, Sturm J, Schmoll J, Keilholz U, Saeger HD (1995) Resektion von solitären Lebermetastasen des malignen Melanoms. Chirurg 66: 40–43
Vollmer RT (1989) Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Ann 24: 383–407
Yao WJ, Hoh JA, Glaspy F (1994) Whole-body FDG PET imaging for staging of malignant melanoma: is it cost effective? J Nucl Med 35: 8P
Anzai Y, Carroll WR, Quint DJ et al. (1996) Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 200: 135–141
Austin JR, Wong FC, Kim EE (1995) Positron emission tomography in the detection of residual laryngeal carcinoma. Otolaryngol Head Neck Surg 113: 404–407
Bailet JW, Sercarz JA, Abemayor E, Anzai Y, Lufkin RB, Hoh CK (1995) The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 105: 135–139
Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward P H (1992) Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 102: 281–288
Baredes S, Leeman DJ, Chen TS et al. (1993) Significance of tumor thickness in soft palate carcinoma. Laryngoscope 103: 389–393
Batsakis JG (1984) Tumors of the head and neck: clinical and pathological considerations. Williams & Wilkens, Baltimore
Benchaou M, Lehmann W, Slosman DO et al. (1996) The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol Stockh 116: 332–335
Berlangieri SU, Brizel DM, Scher RL et al. (1994) Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 16: 340–346
Black RJ, Gluckman JL, Shumrick DA (1983) Multiple primary tumors of the upper aerodigestive tract. Clin Otolaryngol All Sci 8: 277–281
Braams JW, Pruim J, Freling NJM et al. (1995) Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 36: 211–216
de Braud F, Al-Sarraf M (1993) Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck. Sem Oncol 20: 273–278
van den Brekel MW, Castelijns JA, Snow GB (1994) The role of modern imaging studies in staging and therapy of head and neck neoplasms. Semin Oncol 1994; 21:340–348
Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL (1959) The uptake of a variety of amino-acids into nuclear proteins of tumors and other tissues. Cancer Res 19: 1030–1039
Chaiken L, Rege S, Hoh C et al. (1993) Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 27: 455–464
Di Chiro G (1986) Positron emission tomography using (18F)fluoro-deoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 22: 360–371
Dillon WP, Harnsberger HR (1991) The impact of radiologic imaging on staging of cancer of the head and neck. Semin Oncol 18: 64–79
Deutsche Gesellschaft für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie (1997) Leitlinie Kehlkopfkarzinom. HNO-Mitteilungen 47: 7–15 (auch aktuell jeweils abrufbar über Internet (AWMF-online: http://www.uni-duesseldorf.de/WWW/AWMF/II/hno)
Eichhorn T, Schroeder HG, Glanz H, Schwerk WB (1987) Histologisch kontrollierter Vergleich von Palpation und Sonographie bei der Diagnose von Halslymphknotenmetastasen. Laryngol Rhinol Otol 66: 266–274
van Eijkeren M, De Schryver A, Goethals P et al. (1992) Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET). Acta Oncol 31: 539–543
Feinmesser R, Freeman JL, Feinmesser M et al. (1992) Role of modern imaging in decision-making for elective neck dissection. Head Neck 14: 173–176
Fitzpatrick PJ, Tepperman BS, Deboer G (1984) Multiple primary squamous cell carcinomas in the upper digestive tract. Int J Radiat Oncol Biol Phys 10: 2273–2279
Glazer H, Niemeyer JH, Blafes DM (1986) Neck neoplasms: MRI imaging part I. Initial evaluation. Radiology 160: 343–348
Greven KM, Williams D, Keyes JJ et al. (1994) Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 29: 841–845
Greven KM, Williams D, Keyes JJ et al. (1994) Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 74: 1355–1359
Griffeth LK, Dehdashti F, McGuire AH et al. (1992) PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glu-cose. Radiology 182: 185–194
Gritzmann N (1992) Imaging procedures in diagnosis of laryngeal cancer with special reference to high resolution ultrasound. Wien Klin Wochenschr 104: 234–242
Haberkorn U, Strauss LG, Dimitrakopoulou A et al. (1993) Fluoro-deoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 34: 12–17
Haberkorn U, Strauss LG, Reisser C et al. (1991) Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 32: 1548–1555
Hermanek P, Sobin LH (1992) TNM classification of malignant tumors, 4th ed., 2nd Revision. Springer, Berlin Heidelberg New York
Jabour BA, Choi Y, Hoh CK et al. (1993) Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 186: 27–35
Kau RJ, Alexiou C, Laubenbacher C, Ziegler S, Schwaiger M, Arnold W (1998) Positron-Emission-Tomography (PET) for the preoperative staging of head- and neck-tumours. Br J Cancer 77:12
Kau RJ, Laubenbacher C, Saumweber D, Wagner-Manslau C, Schwaiger M, Arnold W (1994) Präoperatives Tumorstaging mittels Endoskopie, Magnetresonanztomographie, Somatosta-tinszintigraphie und Positronenemissionstomographie. Oto-rhinolaryngol Nova 4: 292–299
Kotwall C, Sako K, Razack MS et al. (1987) Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 154:439–442
Lapela M, Grenman R, Kurki T et al. (1995) Head and neck cancer: detection of recurrence with PET and 2-[F-18]Fluoro-2-deoxy-D-glucose. Radiology 197 :205–211
Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ et al. (1995) Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamouscell carcinomas. J Nucl Med 36:1747–1757
Lenz M, Bongers H, Ozdoba C, Skalej M (1989) Klinische Wertigkeit der Computertomographie beim prätherapeutischen T-Staging von orofazialen Tumoren. RöFo 151: 138–144
Leskinen-Kallio S, Lindholm P, Lapela M, Joensuu H, Nordman E (1994) Imaging of head and neck tumors with positron emission tomography and (11 C)methionine. Int J Radiat Oncol Biol Phys 30: 1195–1199
Lindholm P, Leskinen KS, Minn H et al. (1993) Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 34: 1711–1716
Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer — a PET study. J Nucl Med 34:1–6
McGuirt WF (1982) Panendoscopy as a screening examination for simultaneous primary tumors in head and neck cancer: a prospective sequential study and review of the literature. Laryngoscope 92: 569–576
McGuirt WF, Greven KM, Keyes JJ et al. (1995) Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol 104: 274–278
Meyer JS, Friedman E, McCrate MM et al. (1983) Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886
Minn H, Paul R, Ahonen A (1988) Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29: 1521–1525
Minn H, Aitasalo K, Happonen RP (1993) Detection of cancer recurrence in irradiated mandible using positron emission tomography. Eur Arch Otorhinolaryngol 250: 312–315
Minn H, Lapela M, Klemi PJ et al. (1997) Prediction of survival with Fluorine-18-Fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38: 1907–1911
Mukherji SK, Drane WE, Tart RP, Landau S, Mancuso AA (1994) Comparison of thallium-201 and F-18 FDG SPECT uptake in squamous cell carcinoma of the head and neck. Am J Neuroradiol 15: 1837–1842
Mukherji SK, Drane WE, Mancuso AA, Parsons JT, Mendenhall WM, Stringer S (1996) Occult primary tumors of the head and neck: detection with 2-[F-18] fluoro-2-deoxy-D-glucose SPECT. Radiology 199: 761–766
Okada J, Yoshikawa K, Itami M et al. (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33: 325–329
Quetz JU, Rohr S, Hoffmann P, Wustrow J, Mertens J (1991) B-im-age sonography in lymph node staging of the head and neck area. A comparison with palpation, computerized and magnetic resonance tomography. HNO 39: 61–63
Rege S, Maass A, Chaiken L, et al. (1994) Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 73: 3047–3058
Rege SD, Chaiken L, Hoh CK et al. (1993) Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 189: 807–812
Reisser C, Haberkorn U, Dimitrakopoulou SA, Seifert E, Strauss LG (1995) Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 121: 272–276
Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging) (1995) Task Force Report. Guidelines for Clinical Use of Cardiac Radionuclide Imaging. JACC 25: 521–527
Reske SN (1997) Konsensus-Onko-PET. Nuklearmedizin 36: 45–46
Schipper JH, Schrader M, Arweiler D, Muller S, Sciuk J (1996) Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor. HNO 44: 254–257
Seifert E, Schadel A, Haberkorn U, Strauss LG (1992) Evaluating the effectiveness of chemotherapy in patients with head-neck tumors using positron emission tomography (PET scan). HNO 40: 90–93
Som PM (1992) Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. Am J Roentgenol 156: 961–969
Spitz MR (1993) Epidemiology and risk factors for head and neck cancer. Sem Oncol 21: 281–288
Steiner W (1993) Early detection of cancer in the upper aerodige-stive tract, Part I. HNO 41: 360–367
Steinkamp HJ, Maurer J, Heim T, Knobber D, Felix R (1993) Magnetic resonance tomography and computerized tomography in tumor staging of mouth and oropharyngeal cancer. HNO 41: 519–525
Wagner-Manslau C, Laubenbacher C, van de Flierdt E et al. (1992) MRT bei Tumoren im Kopf-Halsbereich. Röntgenpraxis 45:64–70
Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR (1993) Anatometabolic tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 34: 1190–1197
Wong WL, Hussain K, Chevretton E et al. (1996) Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images. Am J Surg 172:628–632
Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25: 79–83
Adler LP, Bloom AD (1993) Positron emission tomography of thyroid masses. Thyroid 3: 195–200
Akslen LA (1993) Prognostic importance of histological grading in papillary carcinoma. Cancer 72: 2680–2685
Balone HR, Fing-Bennett D, Stoffer SS (1992)99mTc-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid. J Nucl Med 33: 1393–1395
Baqai FH, Conti PS, Singer PA, Spencer CA, Wang CC, Nicoloff JT (1994) 18F-FDG-PET scanning — a diagnostic tool for detection of recurrent and metastatic differentiated thyroid cancers. Abstract, 68th annual meeting of the American Thyroid Association, Chicago, p 9
Becker W, Spiegel W, Reiners C, Börner W (1986) Besonderheiten bei der Nachsorge des C-Zell-Karzinoms. Nuklearmediziner 9: 167–181
Biersack HJ, Hotze A (1991) The clinician and the thyroid. Eur J Nucl Med 18: 761–778
Briele B, Hotze AL, Kropp J et al. (1991) A comparison of 201T1 and 99mTc-MIBI in the follow-up of differentiated thyroid carcinoma. Nucl Med 30: 115–124
Conti PS, Durski JM, Grafton ST, Singer PA (1996) PET imaging of locally recurrent and metastatic thyroid cancer. J Nucl Med 37: 135P
Dadparvar S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS, Slizofski WJ (1995) Clinical utility of technetium-99 m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur J Nucl Med 22: 1330–1338
Dai G, Levy O, Carrasco N (1996) Cloning and characterization of the thyroid iodide transporter. Nature 379: 458–460
Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24: 1342–1348
Easton E, Coates D, McKusick A, Borchert R, Zuger J (1995) Concurrent FDG F-18 thyroid PET imaging in I-131 therapy patients. J Nucl Med 36: 197
Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37: 1468–1472
Gallowitsch HJ, Kresnik E, Mikosch P, Pipam W, Gomez I, Lind P. (1996) Tc-99 m tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma — preliminary results. Nucl Med 35: 230–235
Georgi P, Emrich D, Heidenreich P, Moser E, Reiners C, Schicha H (1992) Radiojodtherapie des differenzierten Schilddrüsenkarzinoms. Empfehlungen der Arbeitsgemeinschaft Therapie der Deutschen Gesellschaft für Nuklearmedizin. Nuklearmedizin 31: 151–153
Grünwald F, Menzel C, Bender H et al. (1998) Redifferentiation induced radioiodine uptake in thyroid cancer. J Nucl Med, im Druck
Grünwald F, Menzel C, Bender H et al. (1997) Comparison of 18FDG-PET with 131Iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7: 327–335
Grünwald F, Ruhlmann J, Ammari B, Knopp R, Hotze A, Biersack HJ (1988) Experience with a high-dose concept of differentiated metastatic thyroid cancer therapy. Nucl Med 27: 266–271
Grünwald F, Schomburg A, Bender H et al. (1996) Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23: 312–319
Joensuu H, Ahonen A (1987) Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 28: 910–914
Konsensus — Onko-PET (1997) Ergebnisse der 2. interdisziplinären Konsensuskonferenz im Ulm, 12.9.97. Nuklearmedizin 36: 45–46
Köster C, Ehrenheim C, Burchert W, Oetting G, Hundeshagen H (1996) F-18-FDG-PET, MRT und CT in der Nachsorge des medullären Schilddrüsenkarzinoms. Nuklearmedizin 35: A60
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N (1994) Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 35: 104–112
Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, Tamahashi N (1995) Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 36: 484–492
Matthaei S, Trost B, Hamann A et al. (1995) Effect of in vivo thyroid hormone status on insuline signalling and GLUT1 and GLUT4 glucose transport systems in rat adipocytes. J Endocrinol 144: 347–357
Menzel C, Grünwald F, Schomburg A, Palmedo H, Bender H, Späth G, Biersack HJ (1996) „High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 37:1496–1503
Messa C, Landoni C, Fridrich L, Lucignani G, Striano G, Riccabona G, Fazio F (1996) [F-18]FDG uptake in metastatic thyroid carcinoma prior and after I-131 therapy. Eur J Nucl Med 23: 1097
Nemec J, Nyvltova O, Blazek Tb et al. (1996) Positive thyroid cancer scintigraphy using technetium-99 m methoxyisobutylisonitrile. Eur J Nucl Med 23: 69–71
Pirro JP, Di Rocco RJ, Narra RK, Nunn AD (1994) Relationship between in vitro transendothelial permeability and in vivo single-pass brain extraction. J Nucl Med 35: 1514–1519
Piwinica-Worms D, Kronauge JF, Chiu ML (1990) Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells, mitochondrial and plasma membrane potential dependence. Circulation 82:1826–1838
Platz D, Lübeck M, Beyer W, Grimm C, Beuthin-Baumann B, Gratz KF, Hotze LA (1995) Einsatz der [18F]-deoxyglucose-PET (FDG-PET) in der Nachsorge von Patienten mit differenziertem und medullärem Schilddrüsencarcinom. Nucl Med 34: 152
Raue F (1997) Chemotherapie bei Schilddrüsenkarzinomen: Indikation und Ergebnisse. Onkologe 3: 55–58
Raue F, Frank-Raue K (1997) Gehört die Calcitoninbestimmung zur Abklärung der Struma nodosa? Dtsch Ärztebl 94: 855–856
Reiners C (1993) Radiojodtherapie — Indikation, Durchführung und Risiken. Dtsch Ärztebl 90: 2217–2221
Schober O, Heintz P, Schwarzrock R, Dralle H, Gratz KF, Döhring W, Hundeshagen H (1986) Schilddrüsen-Carcinom: Rezidiv-und Metastasensuche; Sonographie, Röntgen und CT. Nuklearmediziner 9: 139–148
Simon D (1997) Von limitierter bis erweiterter Radikalität der Operation beim Schilddrüsenkarzinom. In: Roth et al. (eds) Klinische Onkologie. Huber, Bern: 347–357
Simon D, Köhrle J, Schmutzler C, Mainz K, Reiners C, Röher HD (1996) Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 104 [Suppl 4]: 13–15
Sisson JC, Ackermann RJ, Meyer MA (1993) Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrin Metabol 77: 1090–1094
Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G (1993) TNM-Atlas. Illustrierter Leitfaden zur TNM/pTNM-Klassifikation maligner Tumoren/International Union Against Cancer/Union Internationale Contre le Cancer (UICC). Springer, Berlin Heidelberg New York, p 58
Tatsch K, Weber W, Rossmüller B, Langhammer H, Ziegler S, Hahn K, Schwaiger M (1996) F-18 FDG-PET in der Nachsorge von Schilddrüsencarcinom-Patienten mit hTg-Anstieg aber fehlender Iod- und Sestamibi-Speicherung. Nuklearmedizin 35: A34
Yoshioka T, Takahashi H, Oikawa H et al. (1994) Accumulation of 2-deoxy-2[18F]fluoro-D-glucose in human cancer heterotransplanted in nude mice: comparison between histology and glycolytic status. J Nucl Med 35: 97–103
Abe Y, Matzuzawa T, Fujiwara T (1990) Clinical assessment of therapeutic effects on cancer using FDG and PET: preliminary study of lung cancer. Int J Radiat Oncol Bio Phys 19:1005–1010
Abdel-Dayem HM, Scott A, Macapinlac H, Larson S (1995) Tracer imaging in lung cancer. Eur J Nucl Med 22: 1355
Baum RP, Rust M, Adams S et al. (1996a) Wertigkeit der Fluor-18-Fluor-Deoxy-Glukose (FDG) Ganzkörper-PET zum präoperativen Staging von Bronchialkarzinomen und Einfluß auf das therapeutische Procedere. Nucl Med 35: A19
Baum RP, Rust M, Adams S et al. (1996b) Influence on patients’ management by whole-body F-18 FDG PET for preoperative staging of non small cell lung cancer. J Nucl Med 37: 121P
Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M (1997) Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 24: 1091–1098
Bleehan NM (1992) Current radiotherapy for non-small-cell lung cancer. Lung Cancer Ther 1: 1–3
Bury T, Dowlati A, Paulus P, Hustinx R, Radermecker M, Rigo P (1996) Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 23: 204–106
Castella J, Buj J, Puzo C, Antón PA, Burgués C (1995) Diagnosis and staging of bronchogenic carcinoma by transtracheal and trans-bronchial needle aspiration. Ann Oncol 6 [Suppl 3]: S21–S24
Chin R, Ward R, Keyes JW et al. (1995) Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 152: 2090–2096
Clorius HH, Lührs H (1990) Das Bronchialkarzinom — Nuklearmedizinische Diagnostik. Radiologe 30: 164–168
Crino L (1995) Chemotherapy on advanced non-small cell lung cancer. The experience of Italian Cooperative Groups. Ann Oncol 6 [Suppl 3]: S45–S47
Cullen MH (1995) Adjuvant and neo-adjuvant chemotherapy of non-small cell carcinoma. Ann Oncol 6 [Suppl 1]: S43–S48
Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP (1993) Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 104/4: 997–1002
Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ: (1995) PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. Chest 108: 441–446
Duhaylongsod FG, Lowe VL, Patz EF, Vaugh AL, Coleman RE, Wolfe WG (1995) Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorax Cardiovasc Surg 110: 130–140
Drings P, Voigt-Moykopf I (1988) Das nicht kleinzellige Bronchialkarzinom. Dtsch Ärztebl 85: B-1469-B-1473
Flehinger BJ, Melamed MR (1994) Current status of screening for lung cancer. Chest Surg Clin North Am 4: 1–15
Frank A, Lefkowitz D, Jaeger S (1995) Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32: 1495–1512
Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J (1996) Decision tree sensitivity analysis for cost — effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 37:1428–1436
Ginsberg RJ (1991) Surgery of higher stage lung cancer. Chest Surg Clin North Am 1: 61–69
Graham EA, Singer JJ (1933) Successfull removal of an entire lung for carcinoma of the bronchus. JAMA 101:1371
Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN (1997) Lymph node staging in non-small-cell lung cancer: evaluation by F-18 FDG positron emission tomography (PET). Thorax 52: 438–441
Gupta NC, Frank AR, Dewan NA et al. (1992) Solitary pulmonary nodules: detection of malignancy with PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose. Radiology 184: 441–444
Gupta NC, Dewan NA, Frank A (1993) Diagnostic evaluation of suspected solitary nodules (SPN) using PET FDG imaing. Chest 104:119 S
Gupta NC, Maloof J, Gunel E (1996) Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37: 943–948
Hebert ME, Lowe VJ, Hoffmann JM, Patz EF, Anscher MS (1996) Positron emission tomography in the pretreatment evaluation and follow-up of non-small-cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 19: 416–421
Hoh CK, Hawkins RA, Glaspy JA et al. (1993) Cancer detection with whole-body PET using 2-(F-18)-fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 17: 582–589
Hoh CK, Schiepers C, Seltzer MA et al. (1997) PET in oncology. Will it replace the other modalities? Sem Nucl Med 27: 94–106
Hör G (1993) Positronen-Emissions-Tomographie (PET) — Von der Forschung zur Klinik. Dtsch Ärztebl 90: 1883–1892
Hör G, Adams S, Baum RP, Hertel A, Adamietz IA, Böttcher HD, Kollath J (1994) Impact of single-photon-emission computed tomography and positron emission tomography on diagnostic oncology. Diagn Oncol 4: 297–321
Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW (1995) Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med 20: 293–298
Hübner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, Dickey J (1996) Differentiating benign from malignant lung lesions using „quantitative” parameters of FDG PET images. Clin Nucl Med 21/12: 941–949
Hughes JMB (1996) F-18-fluorodeoxyglucose PET scans in lung cancer. Thorax 51: S16-S22
Ichiya Y, Kuwabara Y, Otsuka M et al. (1991) Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32:1655–1660
Inoue T, Kim EE, Komaki R et al. (1995) Detection of recurrent or residual lung cancer with FDG-PET. J Nucl Med 36: 788–793
Karp JS, Muehllehner G, Qu H, Yan XH (1995) Singles transmission in volume-imaging PET with 137Cs source. Phys Med Biol 40: 929–944
Knight SB, Delbeke D, Stewart JR, Sandler MP (1996) Evaluation of pulmonary lesions with FDG-PET. Chest 109: 982–988
Knopp MV, Strauss LG, Haberkorn U (1990) PET of the thorax: assessment of its clinical application in tumor staging. Radiology 177: 174
Knopp MV, Bischoff H, Ostertag H et al. (1992) Mediastinal lymph node mapping using F-18 deoxyglucose PET. J Nucl Med 33:828
Knopp MV, Bischoff H, Oberdorfer F, van Kaick G (1992) Positronen Emissions Tomographie des Thorax. Derzeitiger klinischer Stellenwert. Radiologe 32: 290–295
Kubota K, Matsuzawa T, Fujiwara T et al. (1990) Differential diagnosis of lung tumors with positron emission tomography: a prospective study. J Nucl Med 31/12:1927–32
Kubota K, Yamada S, Ishiwata K, Ito M, Ido T (1992) Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer. Clin Nucl Med 17: 877–881
Kubota K, Yamada S, Ishiwata K et al. (1993) Evaluation of the treatment response of lung cancer with positron emission tomography and L-(methyl-C-n) methionine: a preliminary study. Eur J Nucl Med 20: 495–501
Lee JS, Hong WK (1992) Prognostic factors in lung cancer. N Engl J Med 327: 47–48
Lewis P, Griffin S, Marsden P, Gee T, Nunan T, Malsey M, Dussek J (1994) Whole-body F-18 fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344: 1265–1266
Lowe VJ, Hoffman JM, De Long DM, Patz EF, Coleman RE (1994) Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 35/11: 1771–1776
Lowe VJ, De Long DM, Hoffman JM, Coleman RE (1995) Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 36/5: 883–887
Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, Hoffmann JM, Wolfe WG, Coleman RE (1997) Pulmonary abnormalities and PET data analysis: A retrospective study. Radiology 202: 435–439
Lowe VJ, Fletcher JW, Gobar L et al. (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16: 1075–1084
Maul FD, Müller D, Lorenz W, Hör G (1980) Erste Erfahrungen mit Tl-201 in der szintigraphischen Diagnostik von Bronchialtumoren. Nuklearmediziner 4: 335–339
Morgan WE (1995) The surgery of lung cancer. Ann Oncol 6 [Suppl 1]: S33-S36
Mountain CF (1986) A new international staging system for lung cancer. Chest 89 [Suppl 4]: 225S–233S
Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710–1717
Naruke T, Suemasu K, Ishikawa S (1978) Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thor Cardiovasc Surg 76: 832–839
Nolop KB, Rhodes CG, Brudin LH, Peaney RP, Krausz T, Jones T, Hughes JMB (1987) Glucose utilization in vivo by human pulmonary neoplasms. Cancer 60: 2682–2689
Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC (1993) Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188/2: 487–490
Patz EF, Lowe VJ, Hoffmann JM, Paine SS, Harries LK, Goodman PC (1994) Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-(F-18)-2-deoxy-D-glucose. Radiology 191: 379–382
Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM (1995) Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. AJR 164: 1349–1359
Ramanna L (1986) Interest growing in new aerosol imaging methods. Diagn Imag Int 3/4: 3437
Rege SD, Hoh CK, Glaspy JA et al. (1993) Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 72: 82–90
Salathe M, Soler M, Bolliger CT et al. (1992) Transbronchial needle aspiration in routine fiberoptic bronchoscopy. Respiration 59: 5–8
Sasaki M, Ichiya Y, Kuwabara Y et al. (1996) The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small-cell lung cancer: a comparative study with x-ray computed tomography. Eur J Nucl Med 23: 741–747
Sazon DA, Santiago SM, Soo Hoo GW (1996) FDG-PET in the detection and staging of lung cancer. Am J Respir Crit Care Med 153: 417–421
Schiepers C (1997) Role of positron emission tomography in the staging of lung cancer. Lung Cancer 17 [Suppl 1]: S29–S35
Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT (1994) Positron emission tomography of lung tumors and mediastinal lymph nodes using F-18 fluorodeoxyglucose. Ann Thorac Surg 58: 698–703
Scott WJ, Gobar LS, Hauser LG, Sunderland JJ, Dewan NA, Sugimoto JT (1995) Detection of scalene lymph node metastases from lung cancer. Chest 107: 1174–1176
Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL (1998) Oncologic diagnosis with 2-[fluorine-18] fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 207: 431–437
Siegelman SS, Khouri NF, Leo FP, Fishman EK, Braverman RM, Zerhouni EA (1986) Solitary pulmonary nodules : CT assessment. Radiology 160: 307–312
Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, Weder W (1997) Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 202: 441–446
Steinert HC, von Schulthess GK, Wedder W (1998) Effektivität der Ganzkörper-PET mit FDG beim Staging des nicht-kleinzelligen Bronchuskarzinoms bei 100 Patienten. Nuklearmedizin 37: A37
Strauss LG (1996): Die Positronen-Emissions-Tomographie in der onkologischen Therapie- kontrolle. Nuklearmediziner 19: 281–285
Thatcher N, Ranson M, Lee SM, Niven R, Anderson H (1995) Chemotherapy in non-small cell lung cancer. Ann Oncol 6 [Suppl 1]: S83–S95
Toomes H, Delphendal A, Manke HG, Vogt-Moykopf I (1981) Der solitäre Lungenrundherd. Dtsch Ärztebl 37: 1717–1722
Valk PE, Pounds TR, Tesar RD, Hopkins DM, White RI, Orringer MB (1994) Staging of mediastinal non-small-cell lung cancer with FDG-PET, CT, and fusion images: preliminary prospective evaluation. Radiology 191: 371–377
Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK (1996) Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23: 737–743
Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL, Mortelmans LA and the Leuven Lung Cancer Study Group (1997) Mediastinal lymph node staging with FDG-PET scan in patient with potentially operable non-small-cell lung cancer. A prospective analysis of 50 cases. Chest 112: 1480–1486
Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB (1994) Staging of mediastinal non-small cell lung cancer with FDG-PET, CT, and fusion images: preliminary prospective evaluation. Radiology 191: 371–377
Wang, KP, Kelly SJ, Britt JE (1988) Percutaneous needle aspiration biopsy of chest lesions. New instrument and new technique. Chest 93: 993–997
Wang H, Maurea S, Mainolfi C et al. (1997) Tc-99m-MIBI scintigraphy in patients with lung cancer, comparison with CT and fluorine-18 FDG PET imaging. Clin Nucl Med 22: 243–249
Webb WR, Gatsonis C, Zeerhouni EA (1991) CT and MR imaging in staging of non-small cell bronchogenic carcinoma: report of the Radiological Diagnostic Oncology Group. Radiology 178: 705–713
Weber W, Voll B, Treumann T, Watzlowik P, Präuer H, Schwaiger M (1998) Positronen-Emissions-Tomographie mit C-11-Me-thionin und F-18-Fluordeoxyglukose in der Diagnostik des Bronchialkarzinoms. Nuklearmedizin 37: A37
Whitehouse JMA (1994) Management of lung cancer. Standing Medical Advisory Comittee
Winnig AJ, Mclvor J, Seed WA et al. (1986) Interpretation of negative results in fine needle aspiration of discrete pulmonary lesions. Thorax 41: 875–879
Zasadny KR, Kison PV, Quint LE, Wahl RL (1996) Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-(fluorine-18) fluoro-2-deoxy-D-glucose PET scans. Radiology 201: 873–876
Adler LP, Crowe JP, al Kaisi NK, Sunshine JL (1993) Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187: 743–750
Avril N, Dose J, Janicke F et al. (1996a) Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro2-deoxy-D-glucose. J Natl Cancer Inst 88: 1204–1209
Avril N, Dose J, Janicke F et al. (1996b) Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14: 1848–1857
Bassa P, Kim EE, Inoue T et al. (1996) Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37: 931–938
Bastert G, Costa SD (1995) Therapie des Mammakarzinoms. In: Zeller WJ, zur Hausen H (Hrsg) Onkologie. Grundlagen, Diagnostik, Therapie, Entwicklungen. Ecomed, Landsberg
Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Hainan KE (1984) Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1: 131–134
Bender H, Kirst J, Palmedo H, Schomurg A, Wagner U, Ruhlmann J, Biersack HJ (1997) Value of 18F-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17: 1687–1692
Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL (1951) Intratumoral distribution of tritiated fluoro-deoxyglucosein breast carcinoma: 1. are inflammatory cells important. J Nucl Med 36: 1854–1861
Brown RS, Leung Y, Fisher SJ, Frey KA, Ethier SP, Wahl RL (1996) Intratumoral distribution of tritiated-FDG in breast carcino-mae-correlation between Glut-1 expression and FDG uptake. J Nucl Med 37: 1042–1047
Bruce DM, Evans NT, Heys SD et al. (1995) Positron emission tomography: 2-deoxy-2 F18-fluoro-D-Glucose uptake in locally advnaced breast cancers. Eur J Surg Oncol 21: 280–283
Chaiken L, Rege S, Hoh C et al. (1993) Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 27: 455–464
Cherry SR, Carnochan P, Babich JW, Serafini F, Rowell NP, Watson IA (1990) Quantitative in vivo measurements of tumor perfusion using rubidium-81 and positron emission tomography. J Nucl Med 31: 1307–1315
Crowe JP Jr, Adler LP, Shenk RR, Sunshine J (1994) Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1: 132–140
Dedashti F, McGuire AH, Van Brocklin HF et al. (1991) Assessment of 21-[18F] fluoro-16 alphaethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 32: 1532–1537
Dedashti F, Mort-Imer JE, Siegel BA et al. (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36: 1766–1774
Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP (1978) Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of 2-Deoxy-2-(18F) fluoro-D-glucose. J Nucl Med 19:1154–1161
Gilles R, Guinebretiere JM, Lucidarme O et al. (1994) Nonpalpable breast tumors: diagnosis with contrastenhanced substraction dynamic MR imaging. Radiology 191: 625–631
Henderson IC, Harris JR, Kinne DW, Hellman S (1989) Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott, Philadelphia, p 925X
Herman G, Janus CL, Schwarz IS, Kriviski S, Bier J, Rabinowitz G (1987) Non-palpable breast lesions — accuracy of prebiopsy mammographic diagnosis. Radiology 65: 323–326
Hoh CK, Hawkins RA, Glaspy JA et al. (1993) Cancer detection with whole-body PET using 2-(18F) fluor-2-deoxy-D-glucose. J. Comput Assist Tomogr 17: 582–589
Holle LH, Trampert L, Lung Kurt S, Villena Heinsen CE, Puschel W, Schmidt S, Oberhausen E (1996) Investigations of breast tumors with fluorine-18-fluorodeoxyglucose and SPECT. J Nucl Med 37: 615–622
Huovinen R, Leskinen Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M (1993) Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 67: 787–791
Inoue T, Kim EE, Wong FC et al. (1996) Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med 37: 1472–1476
Jacobs M, Mantil J, Peterson C et al. (1995) FDG-PET in breast cancer. J Nucl Med 35: 142P
Jackson VP (1990) The role of ultrasound in breast imaging. Radiology 177: 305–311
Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer — a method for early therapy evaluation? J Clin Oncol 13: 1470–1477
Kallinowski F, Schlenger KH, Runkel S, Kloes M; Stohrer M; Okunieff P; Vaupel P (1989a) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49: 3759–3764
Kallinowski F, Schlenger KH, Kloes M, Stohrer M, Vaupel P (1989b) Tmor blood flow: the principle modulator of oxidative and glycolytic metabolism, and of the metabolic milieu of human tumor xenografts in vivo. Int J Cancer 44: 266–272
Kubota K, Matsuzawa T, Amemiya A et al. (1989) Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 13: 1097–1098
Leskinen Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Joensuu H (1991) Uptake of l1C-methionine in breast cancer studied by PET. An assaciation with the size of S-phase fraction. Br J Cancer 64: 1121–1124
Lindholm P, Min E, Leskinen Kallio S, Bergmann J, Ruotsalainen, Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer — a PET study. J Nucl Med 34: 1–6
McGuire AH, Dedashti F, Siegel BA et al. (1991) Positron tomographic assessment of 16 alpha [18F] fluoro-17 beta-estradiol uptake in metastatic breast-carcinoma. J Nucl Med 32:1526–1531
Minn H, Soini I (1989) [18F] fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 15: 61–66
Minn H, Leskinen Kallio S, Lindholm P, Bergmann J, Ruotsalainen U, Teras M, Haaparanta M (1993) (18F) fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Compu Assist Tomogr 17: 115–123
Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA (1988) Breast cancer: PET imaging of estrogen receptors. Radiology 169: 45–48
Moore MP, Kinne DW (1996) Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. Important Adv Oncol 19: 245–250
Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hor-tobagyi GN, Tilbury RS (1993) Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71: 3920–3925
Palmedo H, Bender H, Grünwald F, Mallmann P, Zamora PO, Krebs D, Biersack HJ (1997) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99 m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. J Nucl Med, in press
Phelps ME, Mazziotta JC, Schelbert HR (eds) (1986) Positron emission tomography and autoradiography. In: Principles and applications for the brain and heart. Raven, New York
Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Gohring UJ, Schomacker K, Schicha H (1996) Qualitative [18F] FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 23: 618–623
Schelstraete K, Simons M, Deman J et al. (1982) Uptake of 13N-ammonia by human tumors as studied by positron emission tomography. Br J Radiol 55: 797–804
Thomas DG, Duthie NL (1968) Use of 2-deoxy-D-glucose to test for the completeness of surgical vagotomy. Gut 9: 125–128
Utech CI, Young CS, Winter PF (1996) Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23: 1588–1593
Wahl RL, Kaminski MS, Ethier SP, Hutchins GD (1990) The potential of 2-deoxy-2-[i8F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 3/1:1831–1835
Wahl RL, Cody R, Hutchins G, Mudgett E (1991a) Positron emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F] fluoro-D-glucose [letter]. N Engl J Med 324: 200
Wahl RL, Cody RL, Hutchins GD, Mudgett E (1991b) Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-i8]-fluoro-2-deoxy-D-glucose. Radiology 179: 765–770
Wahl RL, Henry CA, Ethier SP (1992) Serum glucose: effect on tumor and normal tissue accumulation of 2F -[18] fluoro-2-de-oxy-D-glucose in rodents with mammary carcinoma. Radiology 183: 643–647
Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemohormono-therapy using positron emission tomography: initial evaluation. J Clin Oncol 11: 2101–2111
Wahl RL, Helvie MA, Chang AE, Andersson I (1994) Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 35: 372–875
Warburg O (1930) The metabolism of tumours. Constabel, London
Warburg O (1956) On the origin of cancer cells. Science 123:309–314
Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T (1992) Measurements of blood flow and exchanging water space in breast tumors using positron emission, tomography: a rapid and noninvasive dynamic method. Cancer Res 52:1592–1597
Yang D, Kuang LR, Cherif A et al. (z) Synthesis of 18F-fluoroalanine and 18F-fluorotamoxifen for imaging breast tumors.z
Yang DJ, Li C, Kuang LR et al. (1994) Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 55: 53–67
Zincke M, Avril N, Dose J et al. (1997) PET imaging of breast cancer: comparison between FDG uptkae vs. histology and expression of the glucose transporter protein GLUT-1. J Nucl Med 38:250 A
Bares R, Klever P, Hauptmann S et al. (1994) F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192: 79–86
Beger HG, Birk D, Bodner E, Fritsch A, Gall FP, Trede M (1995) 1st die histologische Sicherung des Pankreaskarzinoms Voraussetzung für die Pankreasresektion? Langenbecks Arch Chir 380/1: 62–66
Diederichs CG, Staib L, Glatting G, Vogel J, Brambs H-J, Beger HG, Reske SN (1997) Differentiation of malignant and benign pancreatic disease. J Nucl Med 38/5: 257P (abstr)
Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN (1998a) FDG-PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med, im Druck
Diederichs CG, Sokiranski R, Pauls S, Schwarz M, Guhlmann CA, Glatting G (1998b) FDG-PET von pankreatischen Tumoren: Transmission obligat? Nuklearmedizin, im Druck
Diederichs CG, Sokiranski R, Pauls S et al. (1998c) Prospective comparison of FDG-PET of pancreatic tumors with high end Spiral-CT and MRI. J Nucl Med (abstr), im Druck
Diederichs CG, Pauls S, Schwarz M, (1998d) Dreiphasiges Spiral-CT und Multisequenz MRT von Pankreaskopf-Tumoren: Wozu noch FDG-PET? Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr (abstr), im Druck
Friess H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, Büchler MW (1995) Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 36/5: 771–777
Fröhlich A, Diederichs CG, Staib L, Beger HG, Reske SN (1997) FDG-PET in the detection of pancreatic cancer liver metastases. J Nucl Med 38/5: 145P (abstr)
Higashi T, Tamaki N, Torizuka T et al. (1995) Differentiation of malignant from benign pancreatic tumors by FDG-PET: comparison with CT, US, and endoscopic ultrasonography. J Nucl Med 36: 224P (abstr)
Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA (1996) FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 20/3: 363–369
Inokuma T, Tamaki N, Torizuka T et al. (1995) Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 36/2: 229–235
Kato T, Fukatsu H, Ito K, et al. (1995) Fluorodeoxyglucose positron emission tomography in pancreatic cancer: a unsolved problem. Eur J Nucl Med 22: 32–39
Langen KH, Braun U, Kops ER, Herzog H, Kuwert T, Nebeling B, Feinendegen LE (1993) The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34: 355–359
Ozaki H, Hojo K, Kato H, Kinoshita T, Egawa S, Kishi K (1988) Multidisciplinary treatment for resectable pancreatic cancer. Int J Pancreatol 3: 249–260
Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, Beger H-G (1997) Overexpression of glucose trans-porter-1 and increased FDG-uptake in pancreatic carcinoma. J Nucl Med 38: 1344–1347
Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN (1995) 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation [see comments]. Radiology 195/2: 339–344
Teusch M, Buell U (1996) Classification of pancreatic tumors by FDG-PET: comparison of visual and quantitative image interpretation by ROC-analysis. J Nucl Med 37/5: 140P (abstr)
Zimny M, Bares R, Faß J et al. (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24: 678–682
Falk PM, Gupta NC, Thorson AG et al. (1994) Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 37: 153–156
Gupta NC, Falk PM, Frank AL, Thorson AM, Frick MP, Bowman B (1993) Pre-operative staging of coloretal carcinoma using positron tomography. Nebr Med J 78/2: 30–35
Haberkorn U, Strauss LG, Dimitrakopoulou A (1991). PET Studies of FDG metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 32: 1485–1490
Ito K, Kato T, Tadokoro M (1992) Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 182: 549–552
Mayer RJ Tumoren des Dünn- und Dickdarms (1995) In: Schmailzl KJG (Hrsg) Harrisons Innere Medizin Bd 2,13. Aufl. Blackwell Wiss. Verlag, S 1669–1676
Miraldi F, Vesselle H, Faulhaber PF et al. (1989) Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 23: 3–7
Ruhlmann J, Kozak B, Biersack HJ (1996). Sensitivität des PET beim frühen Nachweis des kolorektalen Karzinoms. Tumor Diagn Ther 17: 93–96
Ruhlmann J, Schomburg A, Bender H, Oehr P et al. (1997) Dis Colon Rectum 40/10: 1195–1204
Schiepers C, Penninckx F, De Vadder N et al. (1995). Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 21: 517–522
Strauss LG, Corius JH, Schlag P (1989). Recurrence of colorectal tumors: PET evaluation. Radiology 170: 329–332
Thoeni RF (1997) Colorectal cancer. Radiologic staging. Radiol Clin North Am 35: 457–485
Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK (1996). Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23: 737–743
Vitola JV, Delbeke D, Sandler MP et al. (1996). Am J Surg 171: 21–26
Barzen G, Cordes M, Langer M, Friedmann W, Mayr AC, Felix R (1990) Wertigkeit der Radioimmunszintigraphie im Vergleich zur CT in der Diagnostik und Verlaufskontrolle des primären Ovarialkarzinoms. Fortschr Röntgenstr 153: 85–91
Bischof-Delaloyle A, Wahl R (1995) How high a level of FDG abdominal activity is considered normal? J Nucl Med 36: 106 (abstr)
Brooks SE (1994) Preoperative evaluation of patients with suspected ovarian cancer. Gynecol Oncol 55: 80–90
Buist MR, Golding RP, Burger CW et al. (1994) Comparative evaluation of diagnositc modalities in ovarian carcinoma with emphasis on CT and MR. Gynecol Oncol 52: 191–198
Burghardt E, Girardi F, Lahousen M et al. (1991) Patterns of pelvic and paraaortic lymphnode involvement in ovarian cancer. Gynecol Oncol 40: 103–106
Buy JN, Ghossain MA, Sciot C et al. (1991) Epithelial tumors of the ovary: CT findings and correlation with US. Radiology 178: 811–818
Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329: 1550–1559
Carrasquillo JA, Sugarbaker P, Colcher D et al. (1988) Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody. Radiology 167: 35–40
Casey MJ, Gupta NC, Muths CK (1994) Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 53: 331–338
Chou C, Chang C, Yao B, Kuo H (z) Color Doppler ultrasonography and serum Ca 125 in the differentiation of benign and malignant ovarian tumors. J Clin Ultrasound 22: 491–496
DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, Nagell JR (1997) Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 65: 408–414
Forstner R, Hricak H, Icchipinti KA, Powell CB, Frankel SD, Stern JL (1995) Ovarian cancer: staging with CT and MR imaging. Radiology 197: 619–626
Ghossain MA, Buy JN, Lignères C et al. (1991) Epithelial tumors of the ovary: comparison of MR and CT findings. Radiology 181: 863–870
Giunta S, Venturo I, Mottolese M et al. (1994) Noninvasive monitoring of ovarian cancer: improved results using CT with intraperitoneal contrast combined with immunocytology. Gynecol Oncol 53: 103–108
Granowska M, Mather SJ, Britton KE (1991) Diagnostiv evaluation on 111In and 99mTc radiolabeled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery. Nucl Med Biol 18: 413–424
Hata K, Hata T, Manabe A, Sugimura K, Kitao M (1992) A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 80: 922–926
Hoskins WJ (1993) Surgical staging and cytoreductive surgery of epithelial ovarain cancer. Cancer 71 [Suppl]: 1534–1540
Hübner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E (1993) Assessment of primary and metastatic ovarian cancer by positron emission tomographic (PET) using 2-[18-F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 51: 192–204
Karlan BY, Hoh C, Tse N, Futoran R, Hawkins R, Glaspy J (1993) Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. Gynecol Oncol 49: 383–388
Karlan BY, Platt LD (1995) Ovarian cancer screening. The role of ultrasound in early detection. Cancer 76: 2011–2015
Krag DN (1993) Clinical utility of immunoscintigraphy in managing ovarian cancer. J Nucl Med 34: 545–548
Lapela M, Leskinen-Kallio S, Varpula M et al. (1995) Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med 36: 2196–2200
Method MW, Serafini AN, Averette HE, Rodriguez M, Penalver MA, Sevin BU (1996) The role of radioimmunscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. Cancer 77: 2286–2293
Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP (1998) Elimination of artifactual accumulation of FDG in PET imaging of colorectal Cancer. Clin Nucl Med 23: 3–7
Römer W, Avril N, Dose J et al. (1997) Metabolische Charakterisierung von Ovarialtumoren mit der Positronen-Emissions-Tomographie und F-18-Fluordeoxyglukose. Fortschr Röntgenstr 166: 62–68
Sobin LH, Wittekind CH (1997) TNM classification of malignant tumours. Wiley-Liss, New York, pp 152–156
Soper JT (1996) Malignancies of the ovary and Fallopian tube. In: Sevin BU (ed) Multimodality therapy in gynecologic oncology. Thieme, Stuttgart New York pp 135–190
Steichen-Gersdorf E, Gallion HH, Ford D et al. (1994) Familial site-specific ovarian cancer is linked to BRCAi on 17q12–21. Am J Hum Genet 55: 870–875
Tekay A, Jouppila P (1996) Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 75: 316–329
Tibben JG, Massuger LF, Ciaessens RA et al. (1992) Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab’ in patients suspected of ovarian cancer. Nucl Med Commun 13: 885–893
Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossmann HB, Fisher S (1991) 18F-2-Deoxy-2-Fluoro-D-Glucose uptake into human tumor xenografts. Cancer 67: 1544–1550
Yancik R (1993) Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71: 517–523
Zimny M, Schröder W, Wolters S, Cremerius U, Rath W, Bull U (1997a) 18F-Fluordeoxyglukose PET beim Ovarialkarzinom: Methodik und erste Ergebnisse. Nuklearmedizin 36: 228–233
Zimny M, Schröder W, Wolters S, Cremerius U, Rath W, Bull U (1997b) F-18-FDG-PET to diagnose and to stage ovarian cancer: preliminary results. Eur J Nucl Med 24: 924 (abstr)
Aass N, Fossa SD, Ous S, Lien HH, Stenwig AE, Paus E, Kaalhus O (1990) Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-seminomatous testicular cancer? Br J Urol 65: 385–390
Arbeitsausschuß Positronen-Emissions-Tomographie der DGN (1997) Konsensus-Onko-PET. Nuklearmedizin 36: 45–46
Bachor R, Kocher F, Gropengiesser F et al. (1995) Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results. Urologe A 34:138–142
Bender H, Schomburg A, Albers P et al. (1996) Grenzen von Ganz-körper-FDG-PET beim Staging von Hoden-Tumoren. Nuklearmedizin 35: A54
Borchers H, Sohn M, Müller-Leisse C, Fischer N, Jakse G (1991) Growing teratoma syndrome. Onkologie 14 [Suppl 4]: 13
Boring CC, Squires TS, Tong T (1993) Cancer statistics 1993. Ca Cancer J Clin 43: 7–26
Carlsson-Farrelly E, Boquist L, Ljungberg B (1995) Accuracy of clinical staging in non-seminomatous testicular cancer — a single center experience of retroperitoneal lymph node dissection. Scand J Urol Nephrol 29: 501–506
Cremerius U, Effert PJ, Adam G et al. (1998a) FDG-PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 39: 815–822
Cremerius U, Adam G, Zimny M, Jakse G, Bull U (1998b) Vergleich von FDG-PET, CT und Tumormarkern beim Hodentumor-Staging. Nuklearmedizin 37: A10
Dieckmann KP, Boeckmann W, Brosig W, Jonas D, Bauer HW (1986) Bilateral testicular germ cell tumors. Cancer 57: 1254
Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle (1993) Primary retroperitoneal lymph node dissection in clinical stage I nonseminomatous germ cell testis cancer. Br J Urol 71: 326
Freedman LS, Jones WG, Peckham MJ et al. (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2: 294–298
Fung CY, Kalish LA, Brodsky GL, Richie JP, Garnick MB (1988) Stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathology. J Clin Oncol 6: 1467–1473
Garnick MB (1994) Testicular Cancer. In: Harrison’s principles of internal medicine, 13th edition. McGraw-Hill, New York pp 1858–1861
Klepp O, Olsson AM, Henrikson H et al. (1990) Prognostic factors in clinical stage I non-seminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 8: 509–518
Mead GM, Stenning SP, Parkinson ML (1992) The second Medical Research Council Study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 10: 85–94
Moul JW, Melarthy WF, Fernendez EB, Sesterhenn JA (1994) Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage I nonseminomatous testicular cancer. Cancer Res 54: 362–364
Otto T, Goepel M, Seeber S, Rübben H (1993) Delayed retroperitoneal lymph node excision in treatment of advanced nonseminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor. Urologe A 32: 189–193
Peckham MJ, Freedman LS, Jones WG et al. (1988) Der Einfluß der Histopathologic auf die Rezidivwahrscheinlichkeit bei Patienten mit nichtseminomatösen Hodenkarzinomen im Stadium I nach alleiniger Orchiektomie. In: Schmoll HJ, Weißbach L (Hrsg) Diagnostik und Therapie von Hodentumoren. Springer, Berlin Heidelberg New York Tokyo, S 152–160
Read G, Stenning SP, Cullen MH et al. (1992) Medical research council prospective study of survaillance for stage I testicular teratoma. J Clin Oncol 10: 1762
Reinhardt M, Müller-Mattheis V, Vosberg H, Ackermann R, Müller-Gärtner HW (1997) Staging retroperitonealer Lymphknoten bei Hodenkrebs mit FDG-PET. Nuklearmedizin 36: A33
Reinhardt MJ, Müller-Mattheis V, Gerharz CD, Vosberg HR, Ackermann R, Müller-Gärtner HW (1997) FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy. J Nucl Med 38: 99–101
Schöffski P, Bokemeyer C, Harstrick A, Schmoll HJ (1991) Ätiologie und Epidemiologie von Keimzelltumoren. Onkologie 14 [Suppl 4]:11
Schultz HP, Arends J, Barlebo H et al. (1984) Testicular carcinoma in Denmark 1976–1980. Stage and selected clinical parameters at presentation. Acta Radiol Oncol 23: 249–253
Seppelt U (1988) Validierung verschiedener diagnostischer Methoden zur Beurteilung des Lymphknotenstatus. In: Weißbach L, Bussar-Maatz R (Hrsg) Die Diagnostik des Hodentumors und seiner Metastasen. Karger, Basel, S 154–169
Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemo-therapy germ cell tumor patients. J Clin Oncol 14: 1637–1641
Stomper PC, Fung CY, Socinsky MA, Garnick MB, Richie JP (1987) Detection of retroperitoneal metastases in early-stage nonsemi-nomatous testicular cancer analysis of different CT criteria. AJR 149: 1187–1190
Wannenmacher M, Pfannmüller-Schurr EL, Bruggmoser G (1988) Adjuvante Strahlentherapie der Seminome im Stadium I. In: Schmoll HJ, Weißbach L (Hrsg) Diagnostik und Therapie von Hodentumoren. Springer, Berlin Heidelberg New York Tokyo, S 152–160
Wilson CB, Young HE, Ott RJ et al. (1995) Imaging metastatic testicular germ cell tumors with 18-FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 22: 508–513
Zagars GK (1991) Management of stage I seminoma: radiotherapy. In: Horwich A (ed) Testicular cancer: investigation and management. Chapman & Hall, London pp 83–107
Bares R, Altehöfer C, Cremerius U, Handt S, Osieka R, Mittermayer C, Bull U (1994) FDG-PET for metabolic classification of residual lymphoma masses after chemotherapy. J Nucl Med 35: 131 P
Barrington SF, Carr R (1995) Staging of Burkitfs lymphoma and response to treatment monitored by PET scanning. Clin Oncol R Coll Radiol 7: 334–335
Benchaou M, Lehmann W, Slosman DO, Becker M, Lemoine R, Rufenacht D, Donath A (1996) The role of FDG-PET in the preoperative assessment of head and neck cancer. Acta Otolaryngol Stockh 116/2: 332–335
Cremerius U, Bares R, Weis J et al. (1997) Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG PET. J Nucl Med 38: 26–30
Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G (1995) Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 22/5: 434–442
Glatz S, Kotzerke J, Mogg F, Sandherr M, Heimpel H, Reske SN (1996) Vortäuschung eines mediastinalen Non-Hodgkin-Lym-phomrezidives durch diffuse Thymushyperplasie im 18F-FDG-PET. RöFo 165: 309–310
Hiddemann W, Longo DL, Coiffier B et al. (1996) Lymphoma classification — the gap between biology and clinical management is closing. Blood 88: 4085–4089
Higashi K, Clavo A, Wahl RL (1993) Does FDG uptake measure proloferative activity of human cancer cells ? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34: 414–419
Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GWM, Teule GJJ, Huijgens PC (1993) Early treatment response in malignant lymphoma as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 34: 1706–1710
Hoh CK, Glaspy J, Rosen P et al. (1997) Whole body FDG PET imaging for staging of Hodgkin’s disease. J Nucl Med 38/3: 343–348
Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW (1995) Charaterization of chest masses by FDG positron emission tomography. Clin Nucl Med 20: 293–298
Hughes-Davies L, Tarbell NJ et al. (1997) Stage IA — II B Hodgkin’s disease: management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys 39/2: 361–369
Knopp MV, Bischoff H, Lorenz WJ, van Kaick G (1994) PET imaging of lung tumours and mediastinal lymphoma. Nucl Med Biol 21: 749–757
Lapela M, Leskinen S, Minn HR et al. (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxy-glucose. Blood 86/9: 3522–3527
Lewis PJ, Salama A (1994) Uptake of fluorine-18-fluorodeoxyglu-cose in Sarcoidosis. J Nucl Med 35/10: 1647–1649
McLaughlin A, Magee MA, Greenough R et al. (1990) Current role of gallium scanning in the management of lymphoma. Eur J Nucl Med 16: 755–771
Moog F, Bangerter M, Diederichs CG et al. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) in nodal staging. Radiology 203/3: 795–800
Newman JS, Francis IR, Kaminski MS, Wahl RL (1994) Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 190/1: 111–116
Okada J, Yoshikawa K, Itami M et al. (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33/3: 325–329
Okada J, Oonishi H, Yoshikawa K, Imaseki K, Uno K, Itami J, Arimizu N (1994) FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med 8/2: 109–113
Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B (1995) Predicting malignance grade with PET in Non-Hodgkin’s lymphoma. J Nucl Med 36: 1790–1796
Rosenfeld SS, Hoffmann JM, Coleman RE, Glantz MJ, Hanson MW, Schild SC (1992) Studies of primary central nervous system lymphoma with fluorine-18 fluorodeoxyglucose positron emission tomography. J Nucl Med 33/4: 532–536
Sandrock D, Lastoria S, Magrath IT, Neumann RD (1993) The role of gallium-67 tumor scintigraphy in patients with small, non cleaved cell lymphoma. Eur J Nucl Med 20: 119–122
Stansfield AG, Diebold J, Noel H et al. (1988) Kiel Classification. Lancet 1: 292–293
de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfled DK (1997) Whole body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8 [Suppl 1]: 57–60
Zahner J, Bach D, Marms J, Schneider W, Dierckes K, Grabensee B (1997) Glomerulonephritis und malignes Lymphom. Med Klinik 92: 712–719
Adler LP, Blair HF, Makley JT et al. (1991) Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32: 1508–1512
Bachor R, Kocher F, Gropengiesser F et al. (1995) Positron emission tomograpy. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results. Urol Arch 34: 138–142
Bares R, Effert P, Handt S et al. (1994) Metabolic classification of untreated prostate cancer by use of FDG-PET. J Nucl Med 35: 230P
Bender H, Schomburg A, Albers P et al. (1997) Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 17: 1655–1660
Cronin V, Galantowicz P, Nabi HA (1997) Development of oncology protocol using fluorine-18-FDG: one center’s experience. J Nucl Med Technol 25: 66–69
Delbecke D, Meyerowitz C, Lapidus RL et al. (1995) Optimal cutoff levels of F-18 fluorodexyglucose uptake in the differentiation of low-grade from high grade brain tumors with PET. Radiology 195: 47–52
Dimitrakopoulou-Strauss A, Gutzler F, Strauss LG et al. (1996) PET-Studien mit C-11-Athanol bei der intratumoralen Therapie von hepatozellularen Karzinomen. Radiologe 36: 744–749
Enomoto K, Fukunaga T, Okazumi S et al. (1991) Can fluorode-oxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma. Kaku-Igaku 28: 1353–1356
Flanagan FL, Dehdashti F, Siegel BA et al. (1997) Staging of esophageal cancer with i8F-fluorodexyglucose positron emission tomography. Am J Roentgenol 168: 417–424
Griffeth LK, Dehdashti F, McGuire AH et al. (1992) PET evaluation of soft-tissue masses with fluorine-18-fluoro-2-deoxy-d-glucose. Radiology 182: 185–194
Hoh CK, Rosen PJ, Belldegrun A et al. (1996) Quantitative and whole body FDG PET in the evaluation of suramine therapy in patients with metastatic prostate cancer. J Nucl Med 37: 267P
Hoh CK, Figlin RA, Belldegrum A et al. (1996) Evaluation of renal cell carcinoma with whole body FDG PET. J Nucl Med 37:141P
Kern KA, Brunetti A, Norton JA et al. (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29: 181–186
Kim E, Chung SK, Hayne TP et al. (1992) Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 12: 269–279
Kocher F, Bachor R, Stollfuss JC et al. (1995) Positron-emission-tomography of urinary bladder carcinoma. Eur J Nucl Med 20: 888
Kosuda S, Grossman HB, Kison PV et al. (1996) Preliminary FDG-PET study in patients with bladder cancer. J Nucl Med 37: 260P
Laubenbacher C, Hofer C, Avril N et al. (1995) F-18 FDG PET for differentiation of local recurrent prostatic cancer and scar. J Nucl Med 36: 198 P
Miyauchi T, Brown RS, Grossman HB et al. (1996) Correlation between visualization of primary renal cancer by FDG-PET and histopthological findings. J Nucl Med 37: 64 P
Mogard J, Kihlstrom L, Ericson K et al. (1994) Recurrent tumor vs radiation effects after gamma knife radiosurgery of intracerebral metastases: diagnosis with PET-FDG. J Comput Assist Tomogr 18: 177–181
Reinhardt M, Mueller-Matheis V, Larisch R et al. (1995) Time activity analysis improves specificity of FDG-PET in staging of pelvic lymph node metastases. Eur J Nucl Med 22: 803
Shreve P, Gross MD, Wahl RL (1995) Detection of prostate cancer metastases with FDG. J Nucl Med 36: 189P
Torizuka T, Tamaki N, Inokuma T et al. (1994) Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 35: 1965–1969
Yeh SDJ, Imbriaco M, Garza D et al. (1995) Twenty percent of hormone resistant prostate cancer are detected by PET-FDG whole body scanning. J Nucl Med 36: 198 P
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Alexiou, C. et al. (1998). Klinische Indikationen. In: Rühlmann, J., Oehr, P., Biersack, HJ. (eds) PET in der Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09242-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-09242-2_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-09243-9
Online ISBN: 978-3-662-09242-2
eBook Packages: Springer Book Archive